Key Highlights
- Provexis (LSE:PXS) rose 2.13% on 2 October 2026 following publication of its final results on 30 September 2026.
- Results were published on time, a contrast to last year when an audit delay led to a temporary trading suspension.
- Investors remain focused on the planned launch of Fruitflow-based products in China by BYHEALTH, which management has called potentially transformative.
- The company has highlighted strong Demand for Fruitflow II SD, with orders worth several hundred thousand pounds taken after the half-year period.
- The Annual General Meeting is scheduled for October 2026.
Provexis (LSE:PXS) Firms After Annual Results
Shares in Provexis plc (LSE:PXS), the Business that develops, licenses and sells the scientifically proven Fruitflow heart-health functional food ingredient, rose 2.13% on Friday 2 October 2026. The move came shortly after the company published its final results for the year ended 31 March 2026 on 30 September, meeting its reporting deadline.
For a company whose share price trades at around one penny, timely delivery of audited accounts removes a key overhang. Last year, the audit of the 2025 accounts was not completed by the AIM deadline, which led to a short suspension of trading in October 2025. This year's on-time publication has been welcomed by shareholders as a sign of improved governance and operational stability.
Key Reasons Behind the 2.13% Gain
The first driver is the removal of reporting risk. Publishing final results by the end of September means the stock continues trading normally and investors can assess the full-year numbers without uncertainty over the audit process.
The second driver is demand for Fruitflow II SD. At the half-year stage, Provexis said it had taken orders for and sold several hundred thousand pounds of Fruitflow II SD after 30 September 2025, and was handling numerous enquiries from existing and new customers for further direct sales in 2026 and beyond. The company planned at least three further production runs of Fruitflow II SD over the following twelve months, the first of which was expected in February 2026, addressing Supply disruption that had weighed on first-half revenue.
The third and most important driver is the China opportunity. Provexis has worked with BYHEALTH, a listed Chinese dietary supplement business valued at around £2 billion, for more than nine years to support the planned launch of Fruitflow-based products in China. BYHEALTH has been pursuing an extensive regulatory submission to the Chinese State Administration for Market Regulation seeking a new permitted health function claim for foods that demonstrate an anti-platelet effect. Management has described the project as commercially sensitive and potentially transformative, with potential sales volumes at a significant multiple of existing Fruitflow sales.
Why Investors Are Watching LSE:PXS
Fruitflow is a natural, water-soluble extract from tomatoes that has been shown in human trials to reduce the propensity for aberrant blood clotting, which is typically associated with cardiovascular disease. It is sold as an ingredient to Brand owners and as a dietary supplement, Fruitflow+ Omega-3, directly to consumers in the UK and through a cross-border E-commerce distributor in China.
The business has transitioned from relying on a long-standing alliance with DSM to selling Fruitflow II SD directly, while also signing new agreements with DSM covering microbiome-related technology. A successful gut microbiome human study and associated Patent filing point to potential new uses for Fruitflow beyond heart health.
In the year to 31 March 2025, Revenue rose 61% to £1.29 million, demonstrating the impact of direct sales. Investors will now look at how the latest full-year figures compare and how quickly supply constraints have eased.
Market and Social Media Sentiment
Private investor discussion on LSE:PXS centres almost entirely on BYHEALTH and the timing of any Chinese regulatory decision, which could act as a step-change catalyst. Sceptics note the length of time the project has taken and the company's small revenue base, while supporters argue the potential upside justifies patience. The forthcoming AGM in October will be watched for any further colour on China and current trading.
Risks to Monitor
Risks include uncertainty over the timing and outcome of Chinese regulatory approval, supply chain constraints, a small cash balance, customer concentration and the potential need for additional funding.






Please wait processing your request...